A novel mechanism that permits cancer cells to migrate throughout the body has been discovered by a team of researchers from around the world. This finding offers a possible new target for the treatment of metastasis, which is accountable for ninety percent of all deaths caused by cancer.
A shift that happens when lymph drainage is restricted by a primary tumor is that the fluids around the cancer cells become thicker, which causes the cancer cells to migrate at a faster rate. These findings were reported in the journal Nature.
Here we demonstrate that elevated viscosity counterintuitively increases the motility of various cell types on two-dimensional surfaces and in confinement, and increases cell dissemination from three-dimensional tumour spheroids.
Scientists at Johns Hopkins University extended an invitation to the Lewis lab to participate in the study they are leading, given his lab expertise. Lewis is eager for the international research team to continue publishing papers like this one, which is the third one they have put out. He attributes the majority of the work that his team has accomplished to their senior research colleague, Konstantin Stoletov. He warns that the process of developing and testing a medicine could take anywhere from ten to fifteen years, even after a novel therapeutic target has been found.
Lewis is also the founder and CEO of Entos Pharmaceuticals, which is creating a vaccine against COVID-19 that can be kept in a refrigerator, making it simpler to deliver in low- and middle-income nations than vaccines that are currently on the market. The drug was supposed to begin Phase 2 clinical trials in Burkina Faso in September, but the country’s recent coup d’état has halted any further development. Lewis suggests that the trial may be relocated to Senegal, and that the vaccine could potentially be studied in Canada as a booster dose.